What Is Ceftazidime Avibactam Injection?
Ceftazidime Avibactam Injection is a combination antibiotic therapy used to treat serious infections caused by multidrug-resistant (MDR) Gram-negative bacteria. It combines:
-
Ceftazidime: A third-generation cephalosporin antibiotic effective against a broad range of bacteria.
-
Avibactam: A non-β-lactam β-lactamase inhibitor that protects ceftazidime from degradation by certain bacterial enzymes.
This combination enhances the efficacy of ceftazidime against resistant pathogens, including those producing β-lactamases like KPC, ESBLs, and AmpC.
Clinical Indications
Ceftazidime Avibactam Injection is indicated for:
-
Complicated intra-abdominal infections (cIAI): Often used with metronidazole.
-
Complicated urinary tract infections (cUTI), including pyelonephritis.
-
Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible organisms.
It is administered intravenously, typically infused over 2 hours every 8 hours, with treatment duration depending on infection type and patient response.
Efficacy Against Resistant Pathogens
Ceftazidime Avibactam has demonstrated strong in vitro activity against a variety of resistant Gram-negative bacteria, including:PMC+1
-
Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae
-
Extended-spectrum β-lactamase (ESBL)-producing organisms
-
AmpC β-lactamase-producing bacteria
-
Pseudomonas aeruginosa (in certain cases)
Studies have shown that it is particularly effective against ceftazidime-non-susceptible (CAZ-NS) pathogens, offering a viable option for treating infections caused by these resistant strains.
Safety and Side Effects
Ceftazidime Avibactam is generally well-tolerated. Common side effects may include:SpringerLink+9Zuventus+9Lippincott Journals+9Lippincott Journals+10DrugBank+10Wonne International –+10
-
Diarrhea
-
Nausea
-
Headache
-
Injection site reactions
Real-World Experience
Real-world studies have confirmed the effectiveness of Ceftazidime Avibactam in treating MDR infections. For instance, a study involving patients with carbapenem-resistant Enterobacteriaceae (CRE) infections reported a clinical cure rate of 59% at 14 days post-treatment initiation.
Availability and Brand Names
Ceftazidime and Avibactam is marketed under various brand names, including:
-
Avycaz (USA)
-
Zavicefta (EU)
-
Tivibact (India)
The availability and pricing may vary by region, and it is typically administered in hospital settings due to its intravenous formulation.
Website : Jyotilifecar
